Zdeněk Mechl
- Co-authors
- A RejtharA K GhoshMichael MooreJan ŽaloudíkKrsto KolarićMarek PawlickiPavel Krejčı́S. Eckhardt
- Topics
- Cancer Treatment and Pharmacology (7 papers)Cutaneous Melanoma Detection and Management (6 papers)Lung Cancer Research Studies (5 papers)
In The Last Decade
Zdeněk Mechl
37 papers receiving 233 citations
Peers
Comparison fields: 5 of 47
- Oncology 159
- Molecular Biology 76
- Immunology 71
- Cancer Research 34
- Cardiology and Cardiovascular Medicine 32
Countries citing papers authored by Zdeněk Mechl
This map shows the geographic impact of Zdeněk Mechl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zdeněk Mechl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zdeněk Mechl more than expected).
Fields of papers citing papers by Zdeněk Mechl
This network shows the impact of papers produced by Zdeněk Mechl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zdeněk Mechl. The network helps show where Zdeněk Mechl may publish in the future.
Co-authorship network of co-authors of Zdeněk Mechl
This figure shows the co-authorship network connecting the top 25 collaborators of Zdeněk Mechl. A scholar is included among the top collaborators of Zdeněk Mechl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zdeněk Mechl. Zdeněk Mechl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 8 | |
| 3 | Současný stav a perspektivy terapie cílené na kost | 1 |
| 4 | Nežádoucí účinky protinádorové léčby a jejich léčba | 0 |
| 5 | Současná strategie léčby karcinomů ORL oblasti | 0 |
| 6 | [Current treatment strategies for patients with cancers of the head and neck]. | 3 |
| 7 | 10 | |
| 8 | 9 | |
| 9 | 13 | |
| 10 | 12 | |
| 11 | Do some malignant melanoma cells share antigens with the myeloid monocyte lineage? | 5 |
| 12 | 15 | |
| 13 | Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG). | 7 |
| 14 | 6 | |
| 15 | 2 | |
| 16 | 2 | |
| 17 | 14 | |
| 18 | [Cisplatin (platidiame) in the treatment of patients with disseminated breast cancer]. | 1 |
| 19 | 6 | |
| 20 | VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors. | 5 |
About Zdeněk Mechl
Zdeněk Mechl is a scholar working on Oncology, Otorhinolaryngology and Immunology, having authored 42 papers that have together received 255 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Cutaneous Melanoma Detection and Management (6 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Oncology (159 citations), Immunology (71 citations) and Otorhinolaryngology (11 citations). Zdeněk Mechl has collaborated with scholars based in Hungary, Russia and Czechia. Frequent co-authors include A Rejthar, A K Ghosh, Michael Moore, Jan Žaloudík, Krsto Kolarić, Marek Pawlicki, Pavel Krejčı́, S. Eckhardt, Zoltán Hernádi and András Telekes. Their work appears in journals such as Journal of Clinical Pathology, Cancer Immunology Immunotherapy and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.